1983 related articles for article (PubMed ID: 22882665)
1. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
2. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
3. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
4. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
5. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
6. Kala-azar and post-kala-azar dermal leishmaniasis, Assam, India.
Khan AM; Dutta P; Khan SA; Baruah SK; Raja D; Khound K; Mahanta J
Emerg Infect Dis; 2014 Mar; 20(3):487-9. PubMed ID: 24565057
[No Abstract] [Full Text] [Related]
7. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
8. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
9. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
13. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
Dey A; Singh S
Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
[TBL] [Abstract][Full Text] [Related]
14. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
16. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
Rahman KM; Islam S; Rahman MW; Kenah E; Ghalib CM; Zahid MM; Maguire J; Rahman M; Haque R; Luby SP; Bern C
Clin Infect Dis; 2010 Jan; 50(1):73-6. PubMed ID: 19951168
[TBL] [Abstract][Full Text] [Related]
17. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
18. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
[TBL] [Abstract][Full Text] [Related]
19. Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India.
Garapati P; Pal B; Siddiqui NA; Bimal S; Das P; Murti K; Pandey K
PLoS One; 2018; 13(9):e0203407. PubMed ID: 30192805
[TBL] [Abstract][Full Text] [Related]
20. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
